New drug for COVID-19 treatment? CSIR, Laxai Life begin phase II trials for Niclosamide
Niclosamide has been extensively used in the past for treatment of tapeworm's infection in adults as well as children and its safety profile has been tested over time.
- Jun 6, 2021,
- Updated Jun 6, 2021 7:30 PM IST
The Council of Scientific and Industrial Research (CSIR), in collaboration with Hyderabad-based Laxai Life Sciences Pvt Ltd, has initiated phase II clinical trials of anti-helminitic drug Niclosamide for treatment of COVID-19.
"The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of Niclosamide for the treatment of hospitalized COVID-19 patients," the government said in a release on Sunday.
Niclosamide has been extensively used in the past for treatment of tapeworm's infection in adults as well as children. The safety profile of the drug has been tested over time and has been found safe for human consumption at different dose levels.
'Too early to assess impact of second Covid-19 wave': FM Nirmala Sitharaman
The Council of Scientific and Industrial Research (CSIR), in collaboration with Hyderabad-based Laxai Life Sciences Pvt Ltd, has initiated phase II clinical trials of anti-helminitic drug Niclosamide for treatment of COVID-19.
"The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of Niclosamide for the treatment of hospitalized COVID-19 patients," the government said in a release on Sunday.
Niclosamide has been extensively used in the past for treatment of tapeworm's infection in adults as well as children. The safety profile of the drug has been tested over time and has been found safe for human consumption at different dose levels.
'Too early to assess impact of second Covid-19 wave': FM Nirmala Sitharaman